ConductScience.org, home

Paper326604

C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.

Faber OK and 1 other. Diabetes, 1977. Cited by 475 papers, by iCite.

Cite this record

ConductScience Library. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Papers, record 326604. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/326604

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.
PubMed
Journal
Diabetes
PubMed
Year
1977
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
475
iCite
Relative citation ratio, by iCite
16.1
iCite
Revised in PubMed
2022-03-16
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Faber OKO K
2Binder CC

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
C-PeptideMajor topic
Diabetes MellitusMajor topic
GlucagonMajor topic
Islets of LangerhansMajor topic
PeptidesMajor topic
Adolescent
Adult
Blood Glucose
Child
Fasting
Female
Humans
Insulin
Male
Middle Aged

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01480843Simplified Insulin Protocol Using Lantus in ElderlyBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by103

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 475 citations.

PMIDTitleJournalYearIn PapersSource
41376852
Effect of Beta-Cell Function on Glucose Variability When Switching From Insulin Degludec Plus a Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide: Preliminary Results From a Pilot Study.
Int J Endocrinol2025https://conductscience.org/library/papers/41376852PubMed
41214251Clinical, immunogenetic and metabolic characteristics of autoantibody-negative and autoantibody-positive type 1 diabetes.Diabetologia2026https://conductscience.org/library/papers/41214251PubMed
39656436Metabolic, genetic and immunological features of relatives of type 1 diabetes patients with elevated insulin resistance.J Endocrinol Invest2025https://conductscience.org/library/papers/39656436PubMed
38015721High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans.Diabetes2024https://conductscience.org/library/papers/38015721PubMed
36184780Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).Diabetes Obes Metab2023https://conductscience.org/library/papers/36184780PubMed
35574023Glucagon Test Is a Useful Predictor of Withdrawal From Insulin Therapy in Subjects With Type 2 Diabetes Mellitus.Front Endocrinol (Lausanne)2022https://conductscience.org/library/papers/35574023PubMed
34610719Assessment of Insulin Secretion and Insulin Resistance in Human.Diabetes Metab J2021https://conductscience.org/library/papers/34610719PubMed
34510360
Circulating Hematopoietic (HSC) and Very-Small Embryonic like (VSEL) Stem Cells in Newly Diagnosed Childhood Diabetes type 1 - Novel Parameters of Beta Cell Destruction/Regeneration Balance and Possible Prognostic Factors of Future Disease Course.
Stem Cell Rev Rep2022https://conductscience.org/library/papers/34510360PubMed
32775460Association between 1,5-Anhydroglucitol and Acute C Peptide Response to Arginine among Patients with Type 2 Diabetes.J Diabetes Res2020https://conductscience.org/library/papers/32775460PubMed
31745069Human Leukocyte Antigen (HLA) Subtype-Dependent Development of Myasthenia Gravis, Type-1 Diabetes Mellitus, and Hashimoto Disease: A Case Report of Autoimmune Polyendocrine Syndrome Type 3.Am J Case Rep2019https://conductscience.org/library/papers/31745069PubMed
30853818A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.Curr Oncol2019https://conductscience.org/library/papers/30853818PubMed
30788807C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study.Diabetes Ther2019https://conductscience.org/library/papers/30788807PubMed
30392045Capturing residual beta cell function in type 1 diabetes.Diabetologia2019https://conductscience.org/library/papers/30392045PubMed
28494143
Normal meal tolerance test is preferable to the glucagon stimulation test in patients with type 2 diabetes that are not in a hyperglycemic state: Comparison with the change of C-peptide immunoreactivity.
J Diabetes Investig2018https://conductscience.org/library/papers/28494143PubMed
28484968A Practical Review of C-Peptide Testing in Diabetes.Diabetes Ther2017https://conductscience.org/library/papers/28484968PubMed
26849676C-Peptide Level in Fasting Plasma and Pooled Urine Predicts HbA1c after Hospitalization in Patients with Type 2 Diabetes Mellitus.PLoS One2016https://conductscience.org/library/papers/26849676PubMed
26607818Short-term glucagon stimulation test of C-peptide effect on glucose utilization in patients with type 1 diabetes mellitus.Med Biol Eng Comput2015https://conductscience.org/library/papers/26607818PubMed
24843713Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.J Diabetes Investig2013https://conductscience.org/library/papers/24843713PubMed
24843526Analysis of factors influencing postprandial C-peptide levels in Japanese patients with type 2 diabetes: Comparison with C-peptide levels after glucagon load.J Diabetes Investig2011https://conductscience.org/library/papers/24843526PubMed
24843502Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes.J Diabetes Investig2011https://conductscience.org/library/papers/24843502PubMed

See all 103 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GCG2641PubTator's text mininghttps://conductscience.org/library/genes/2641NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/326604

GET https://conductscience.org/api/papers/v1/326604/cited_by?page=2